Qing Huo

Prof. Qing Huo


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in Aging
Verified
Journal Article
Open access
XZXin Zhao
Xin Zhao
XLXiaomin Liu
Xiaomin Liu
AZAiling Zhang
Ailing Zhang
HCHuashuai Chen
Huashuai Chen
QHQing Huo
Qing Huo
CNChao Nie
Chao Nie
Copy number variations (CNVs) have been shown to cause numerous diseases, however, their roles in human lifespan remain elusive. In this study, we investigate the association of CNVs with longevity by comparing the Han Chinese genomes of long-lived individuals from 90 to 117 years of age and the middle-aged from 30 to 65. Our data demonstrate that the numbers of CNVs, especially deletions, increase significantly in a direct correlation with longevity. We identify eleven CNVs that strongly associate with longevity; four of them locate in the chromosome bands, 7p11.2, 20q13.33, 19p12 and 8p23.3 and overlap partially with the CNVs identified in long-lived Danish or U.S. populations, while the other seven have not been reported previously. These CNV regions encode nineteen known genes, and some of which have been shown to affect aging-related phenotypes such as the shortening of telomere length (ZNF208), the risk of cancer (FOXA1, LAMA5, ZNF716), and vascular and immune-related diseases (ARHGEF10, TOR2A, SH2D3C). In addition, we found several pathways enriched in long-lived genomes, including FOXA1 and FOXA transcription factor networks involved in regulating aging or age-dependent diseases such as cancer. Thus, our study has identified longevity-associated CNV regions and their affected genes and pathways. Our results suggest that the human genome structures such as CNVs might play an important role in determining a long life in human.

17 May 2018 in Food & Function
Verified
Journal Article
Closed access
PDF file
WJWenwen Jin
Wenwen Jin
XCXuemin Chen
Xuemin Chen
QHQing Huo
Qing Huo
YCYajie Cui
Yajie Cui
ZYZejun Yu
Zejun Yu
LYLongjiang Yu
Longjiang Yu
Lepidium meyenii Walp. (maca) has been utilized in the Andean region because of its edibleness and medicinal value. The aerial parts of maca (APM) were analyzed for protein, total sugar, vitamins, amino acids, and minerals and its characteristic active ingredients at five different growth stages. The results showed the high protein, total sugar, vitamin C, niacin, potassium, and calcium contents of APM. All 17 amino acids and the characteristic active ingredients, namely, macamide, glucosinolates, adenosine, and total saponins, were detected. We examined the effects of maca plant powders on gastric emptying and intestinal propulsion and the levels of serum motilin and gastrin in atropine-treated mice. Benzyl isothiocyanate (BITC) was investigated to identify the potential active material in APM. The results revealed that both maca plant powders and BITC can promote the gastrointestinal prokinetic efficacy. Thus, APM feature potential as new functional vegetable sources.

30 September 2016 in Bioengineered
Verified
Journal Article
Open access
QLQiang Lin
Qiang Lin
QHQing Huo
Qing Huo
YQYingzhe Qin
Yingzhe Qin
ZZZhuo Zhao
Zhuo Zhao
FTFengyun Tao
Fengyun Tao
This study investigates the preparation of ligustrazine hydrochloride carboxymethyl chitosan and collagen microspheres. This experiment investigates effects of the ratio of carboxymethyl chitosan and collagen blend, water to oil ratio, stirring speed, and other factors on the microsphere properties. The experiment had the following conditions: a 1:2 proportion of carboxymethyl chitosan and collagen, a 1:2 proportion of drugs and materials, a 5:1 proportion of oil phase and water phase, 0.5% of span80, a 600r/min stirring speed, 3 ml of a cross-linking agent, 3 h of cross-linking curing, 1.25 ± 0.05 mm diameter LTH microcapsules, a 54.08% envelop rate, and a 14.16% carrier rate. The microspheres release rate reached 66% within 1 h, then steadily released within 5 h in vitro. The experimental results showed that the ligustrazine hydrochloride microsphere production process was stable and exhibited a good release effect compared with other ligustrazine hydrochloride tablets and pills.

25 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
JYJiaqi Yuan
Jiaqi Yuan
HWHan Wang
Han Wang
YWYunting Wang
Yunting Wang
ZWZijian Wang
Zijian Wang
QHQing Huo
Qing Huo
YSYaxuan Sun
Yaxuan Sun
Alzheimer’s disease (AD) is a degenerative disease of the central nervous system characterized by the progressive impairment of neural activity. Studies have shown that 3,6′-disinapoyl sucrose (DISS) can alleviate the pathological symptoms of AD through the activation of the cAMP/CREB/BDNF signaling pathway. However, the exact biochemical mechanisms of action of DISS are not clear. This study explores metabolism of DISS in an AD mouse model, induced by the microinjection of a lentiviral expression plasmid of the APPswe695 gene into CA1 of the hippocampus. After gavage administration of DISS (200 mg/kg), the kidneys, livers, brains, plasma, urine, and feces were collected for UHPLC–Orbitrap mass spectrometry analysis. Twenty metabolites, including the prototype drug of DISS, were positively or tentatively identified based on accurate mass measurements, characteristic fragmentation behaviors, and retention times. Thus, the metabolic pathways of DISS in AD mice were preliminarily elucidated through the identification of metabolites, such as ester bond cleavage, demethoxylation, demethylation, and sinapic acid-related products. Furthermore, differences in the in vivo distribution of several metabolites were observed between the model and sham control groups. These findings can provide a valuable reference for the pharmacological mechanisms and biosafety of DISS.

1 January 2018 in Open Life Sciences
Verified
Journal Article
Open access
PDF file
XWXiao Wu
Xiao Wu
QHQing Huo
Qing Huo
QQQizhe Quan
Qizhe Quan
XYXiaofang Yang
Xiaofang Yang
NYNa Yu
Na Yu
YWYue Wang
Yue Wang
The main purpose of our study is to optimize the formulation for Ginkgolide B (GB) solid dispersion in order to improve its dissolution in water. For the preparation of GB solid dispersion, we use a solvent method. The optimized formulation consists of GB : PVPK30 = 1:10, PVPK30 as the carrier, and ethanol : dichloromethane = 1:1 as the solvent. They were treated ultrasonically for 10 min at 60°C. The results from scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray diffraction (XRD), and particle size analysis show that the morphological appearance of GB changed significantly in solid dispersion. The original crystal form of GB no longer existed, but it was uniformly dispersed within PVPK30 in a non-crystalline form. It is probably because the -C=O in GB forms hydrogen bonds with the -OH of PVPK30 or urea; this produces a nice solid dispersion and significantly improves the dissolution of GB in water. When GB is in a solid dispersion system, GB’s dissolution in water could be enhanced from 30% to 80%. Furthermore, it may even be produced as a solid agent.

26 August 2020 in Open Chemistry
Verified
Journal Article
Open access
PDF file
JZJuntong Zhou
Juntong Zhou
XWXiao Wu
Xiao Wu
ZZZhanhong Zhao
Zhanhong Zhao
ZWZhenpeng Wang
Zhenpeng Wang
SLShumu Li
Shumu Li
QHQing Huo
Qing Huo
Ginkgolide B (GB) and Puerarin (Pue) are active pharmaceutical ingredients for the treatment of Parkinson’s disease (PD); however, both are poorly water-soluble, which limits their bioavailability. The present study used the niosome vesicle encapsulation technique to prepare a novel GB composite drug. The conditions for GB–Pue niosomal complex preparation were as follows: a hydration temperature of 60°C, a hydrophilic–lipophilic balance of 10.5, a drug–carrier mass ratio of 8:100, and a surfactant–cholesterol mass ratio of 1.5:1. The niosomal complex suspension was uniformly distributed and milky white in color, with no stratification over a duration of 1 month. It had an average particle size of 187.3 nm, a particle-size distribution of 0.237, a GB encapsulation efficiency (EE) of 68.2%, a GB drug-loading rate of 90.1%, a Pue EE of 40.5%, and a Pue drug-loading rate of 83.3%. The optimal storage temperature for the niosomal complex suspension was 4°C. Following an intravenous injection of the niosomal complex suspension into the rat tail, the area under the curve (AUC) from 0 to 4 h was 54.1 h µg mL−1, with a mean residence time (MRT) of 0.96 h, a distribution half-life (T1/2α) of 0.195 h, and a total clearance of 0.003 L h−1 kg−1. The AUC and MRT of the composite prescription were 1.1- and 1.4-times those of the commercial injection, respectively, showing significantly increased sustained release and bioavailability. Moreover, the distribution of GB in the brain tissue was 1.8-times that of the commercial injection. In conclusion, the novel GB niosomal composite drug, with excellent stability, improved pharmacokinetics, and brain tissue distribution, demonstrates great potential for the delivery of GB and Pue for PD therapeutics.